[Comment] Stopping β-blockers long after myocardial infarction
Few areas of cardiovascular pharmacotherapy have changed as much as β-blocker use after myocardial infarction. For decades, β-blockers were prescribed routinely and often indefinitely after myocardial infarction, a practice based on trials from the early 1980s showing reductions in mortality and recurrent events.1 However, those trials preceded routine reperfusion, invasive management, statins, and dual antiplatelet therapy; therefore, their relevance to contemporary post-myocardial infarction p
Few areas of cardiovascular pharmacotherapy have changed as much as β-blocker use after myocardial infarction. For decades, β-blockers were prescribed routinely and often indefinitely after myocardial infarction, a practice based on trials from the early 1980s showing reductions in mortality and recurrent events.1 However, those trials preceded routine reperfusion, invasive management, statins, and dual antiplatelet therapy; therefore, their relevance to contemporary post-myocardial infarction patients is uncertain.